2-溴-1-甲基-1H-咪唑 | 16681-59-7

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 中文名称: 2-溴-1-甲基-1H-咪唑
• 中文别名: 1-甲基-2-溴-1H-咪唑；1-甲基-2-溴咪唑；2-溴-1-甲基咪唑；1H-咪唑,2-溴-1-甲基
• 英文名称: 2-bromo-1-methyl-1H-imidazole
• 英文别名: 2-bromo-1-methylimidazole；2-bromo-N-methylimidazole；2-Brom-1-methyl-imidazol；1-methyl-2-bromoimidazole
• CAS: 16681-59-7
• 化学式: C₄H₅BrN₂
• mdl: MFCD02179525
• 分子量: 161.001
• InChiKey: BANOTGHIHYMTDL-UHFFFAOYSA-N

物化性质

• 沸点：
  172 °C (lit.)
• 密度：
  1.649 g/mL at 25 °C (lit.)
• 闪点：
  >230 °F
• 稳定性/保质期：
  按照规定使用，这种物质不会分解，并且能够避免氧化。

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 安全说明：
  S26
• 危险品运输编号：
  NONH for all modes of transport
• WGK Germany：
  3
• 海关编码：
  2933290090
• 危险品标志：
  Xn
• 危险类别码：
  R22,R41,R38
• 危险标志：
  GHS05,GHS07
• 危险性描述：
  H302,H315,H318
• 危险性防范说明：
  P280,P305 + P351 + P338
• 包装等级：
  III
• 危险类别：
  8
• 储存条件：
  存储于密闭、阴凉、干燥处。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Bromo-1-methyl-1H-imidazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H318: Causes serious eye damage
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-1-methyl-1H-imidazole
CAS number: 16681-59-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C4H5BrN2
Molecular weight: 161.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-1-甲基-1H-咪唑 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 氯仿 为溶剂， 反应 2.0h， 生成 2,5-二溴-1-甲基-1H-咪唑
  参考文献：
  名称：

  [EN] GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE
  [FR] INHIBITEURS DE GLYCOLATE OXYDASE POUR LE TRAITEMENT D'UNE MALADIE

  摘要：

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物，以及使用这种化合物治疗或预防与甘氧酸代谢缺陷相关的疾病或紊乱的方法，例如与甘氧酸氧化酶（GO）或草酸代谢变化相关的疾病或紊乱。这些疾病或紊乱包括与产生过多草酸相关的甘氧酸代谢紊乱，例如原发性高草酸尿症。

  公开号：

  WO2020257487A1
• 作为产物：
  描述：

  N-甲基咪唑 在 溴化氰 作用下， 以 乙腈 为溶剂， 反应 3.0h， 以64%的产率得到2-溴-1-甲基-1H-咪唑
  参考文献：
  名称：

  Reaction of Imidazoles with Cyanogen Bromide: Cyanation at N 1 or Bromination at C 2?

  摘要：

  一些咪唑（1H-、1-甲基-、2-甲基-、4-甲基-、1,2-、1,4-和 1,5-二甲基-、1-乙基-、1-苄基-和 1-丁基-咪唑）在乙腈溶液中发生反应、和 1-丁基咪唑）以及咪唑与 BrCN 的络合物（[Co(NH3)5(imH)](ClO4)3、[Co(NH3)5(im)](ClO4)2 和[Co(NH3)5(1-Meim)](ClO4)3）进行了研究。带有 N-烷基取代基和 C2 位有氢的咪唑反应生成 2-溴产物，而 N-H-咪唑反应生成 N-氰基衍生物。1,2-二甲基咪唑与 BrCN 反应生成的产物无法定性。在这些复合物中，只有[Co(NH3)5(im)](ClO4)2 发生反应，生成 2-溴产物。我们的观察结果表明，咪唑与 BrCN 反应需要环氮原子上的孤对子，并提出了一种可能的机理。报告了 2-甲基咪唑-1-甲腈的 X 射线结构。晶体数据（-143°C）为 C5H5N3：单斜，P21/c，a10-201(5), b 7-110(3), c 7-227(3) Å, β 100-47(2)°, V 515-4(4) Å 3, Z 4, dcalcd 1-380 gcm¯3 。对所有 1278 个数据的细化结构收敛于 Fo >4F(Fo) 的 1183 次反射的 R1 0-0444 和 wR2 0-1259。

  DOI：

  10.1071/c98105

文献信息

• BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas Operations, Inc.

  公开号：US20190300521A1

  公开（公告）日：2019-10-03

  The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为SMARCA2或BRM（靶蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端结合Von Hippel-Lindau E3泛素连接酶的配体，另一端结合靶蛋白的双功能化合物，使得靶蛋白与泛素连接酶靠近以实现靶蛋白的降解（和抑制）。本公开展示了与靶蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由靶蛋白聚集或积累导致的疾病或紊乱。
• Optimized scale up of 3-pyrimidinylpyrazolo[1,5-a]pyridine via Suzuki coupling; a general method of accessing a range of 3-(hetero)arylpyrazolo[1,5-a]pyridines
  作者：Paul A. Bethel、Andrew D. Campbell、Frederick W. Goldberg、Paul D. Kemmitt、Gillian M. Lamont、Abid Suleman

  DOI：10.1016/j.tet.2012.04.094

  日期：2012.7

  an improved synthesis of 3-(hetero)aryl pyrazolo[1,5-a]pyridines (such as 3-(2,5-dichloropyrimidin-4-yl)pyrazolo[1,5-a]pyridine (8)) via an optimized synthesis and Suzuki coupling of 3-pyrazolo[1,5-a]pyridine boronic ester 10. These conditions are applicable to both high throughput chemistry and large scale synthesis of these medicinally important compounds. The scope of this chemistry has been further

  我们已经开发出3-（杂）芳基吡唑并[1,5- a ]吡啶（例如3-（2,5-二氯嘧啶-4-基）吡唑并[1,5- a ]吡啶（8）的合成方法。）通过优化的合成方法和3-pyrazolo [1,5- a ]吡啶硼酸酯10的Suzuki偶联。这些条件适用于这些医学上重要的化合物的高通量化学和大规模合成。该化学反应的范围已进一步扩展到包括新型硼酸酯3-（4,4,5,5-四甲基-1,3,2-二氧杂硼硼烷-2-基）-6,7的合成和偶联-二氢-5 H-吡唑并[5,1- b ] [1,3]恶嗪（43）。
• [EN] SPIRO-FUSED TRICYCLIC MAP4K1 INHIBITORS<br/>[FR] INHIBITEURS DE MAP4K1 TRICYCLIQUES SPIRO FUSIONNÉS
  申请人：BAYER AG

  公开号：WO2021074279A1

  公开（公告）日：2021-04-22

  The present invention relates to Map4K1 inhibitors of formula (I) to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, repectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.

  本发明涉及式(I)的Map4K1抑制剂，以及包含根据本发明的化合物的药物组合物和组合物，以及创新化合物的预防性和治疗性用途，分别用于制造用于治疗或预防疾病的药物组合物，特别是用于肿瘤性疾病，癌症或与异常MAP4K1信号相关的其他紊乱免疫反应或其他紊乱的疾病，作为单一药剂或与其他活性成分组合使用。本发明还涉及使用，分别用于制造用于治疗或预防良性增生、动脉粥样硬化疾病、败血症、自身免疫疾病、血管疾病、病毒感染、神经退行性疾病、炎症性疾病、动脉粥样硬化疾病和男性生育控制的蛋白抑制剂的药物组合物的用途。
• Pyrrolo-pyridine kinase modulators
  申请人：Arnold D. William

  公开号：US20060030583A1

  公开（公告）日：2006-02-09

  The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.

  本发明提供了新型吡咯-吡啶激酶调节剂以及利用这些新型吡咯-吡啶激酶调节剂治疗由激酶活性介导的疾病的方法。
• Visible-light-promoted N-centered radical generation for remote heteroaryl migration
  作者：Chengkou Liu、Chen Cai、Chengcheng Yuan、Qiang Jiang、Zheng Fang、Kai Guo

  DOI：10.1039/d0ob01594f

  日期：——

  An efficient visible-light-mediated organocatalyzed N–H heteroarylation was accomplished via remote heteroaryl ipso-migration.

  通过远程杂芳基ipso-迁移实现了一种高效的可见光介导的有机催化N–H杂芳基化反应。